Oncopeptides says its withdrawal appeal brief for Pepaxto describes the 'missing link' for why elderly myeloma patients have not seen improved survival. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
